A Cancer Innovation Crisis? Misplaced Incentives Promote Marginal Benefits, JAMA Study Says

A study of oncology approvals since 2002 concludes that only 42% represented a “clinically meaningful improvement” in therapy. High prices encourage a “me-too” mentality that directs R&D investment to marginal indications, the authors assert.